Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.17925/EE.2015.11.01.21 http://scihub22266oqcxt.onion/10.17925/EE.2015.11.01.21 C5819057!5819057!29632562     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Endocrinol 2015 ; 11 (1): 21-5 Nephropedia Template TP {{tp|p=29632562|t=2015. GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond ? New Insights 2015 |pdf=|usr=}}{{29632562}} gab.com Text GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond New Insights 2015 JO: Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29632562 #FOAvip Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced for type 2 diabetes therapy nearly 10 years ago, among them short-acting compounds on the basis of the GLP-1-like peptide exendin-4 (exenatide and lixisenatide) and a long-acting GLP-1 RA based on the human GLP-1 sequence (liraglutide). Recently, two novel long-acting GLP-1 RAs on the basis of human GLP-1 sequence, for once-weekly application, have been approved for therapy of type 2 diabetes. Additionally, liraglutide has been approved for treatment of obesity at a higher dose than that used for diabetes therapy. This mini-review gives a short overview of the novel long-acting GLP-1 RAs albiglutide and dulaglutide and also reviews the studies of liraglutide in treatment of obesity leading to its approval for this use. These studies were largely presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in fall 2014. Twit Text FOAVip GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond New Insights 2015 ????Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29632562 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29632562 #FOAvip English Wikipedia <ref>{{Cite pmid|29632562}}</ref> GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond ? New Insights 2015 #MMPMID29632562 Gallwitz B Eur Endocrinol 2015[Apr]; 11 (1): 21-5 PMID29632562show ga Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced for type 2 diabetes therapy nearly 10 years ago, among them short-acting compounds on the basis of the GLP-1-like peptide exendin-4 (exenatide and lixisenatide) and a long-acting GLP-1 RA based on the human GLP-1 sequence (liraglutide). Recently, two novel long-acting GLP-1 RAs on the basis of human GLP-1 sequence, for once-weekly application, have been approved for therapy of type 2 diabetes. Additionally, liraglutide has been approved for treatment of obesity at a higher dose than that used for diabetes therapy. This mini-review gives a short overview of the novel long-acting GLP-1 RAs albiglutide and dulaglutide and also reviews the studies of liraglutide in treatment of obesity leading to its approval for this use. These studies were largely presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in fall 2014. äGLP-1 Receptor Agonists in Type 2 Diabetes and Beyond ? New Insights 2(epmc).pdf DeepDyve Pubget Overpricing